Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cellectis S.A. - American Depositary Shares (NQ: CLLS )

1.460 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 102
Open 1.460
Bid (Size) 1.470 (39)
Ask (Size) 1.520 (6)
Prev. Close 1.460
Today's Range 1.460 - 1.460
52wk Range 1.100 - 3.380
Shares Outstanding 45,484,310
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal
Cellectis, backed by AstraZeneca funding and a multi-year cash runway, is advancing its prioritized allogeneic CAR-T pipeline toward pivotal 2025 milestones. 
Via MarketBeat
The market is filled with gapping stocks in Friday's session.
Today's session on Friday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill

Performance

YTD
-19.34%
-19.34%
1 Month
+11.45%
+11.45%
3 Month
-4.58%
-4.58%
6 Month
-25.89%
-25.89%
1 Year
-44.27%
-44.27%

More News

Read More
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Rubrik Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update
From Cellectis Inc.
Via GlobeNewswire
Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025
From Cellectis Inc.
Via GlobeNewswire
Earnings Scheduled For March 13, 2025
Via Benzinga
Cellectis Presents ‘Smart CAR T’ Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025
From Cellectis Inc.
Via GlobeNewswire
Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB)
From Cellectis Inc.
Via GlobeNewswire
Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting
From Cellectis Inc.
Via GlobeNewswire
Cellectis Provides Business Updates and Financial Results for Third Quarter 2024
From Cellectis Inc.
Via GlobeNewswire
Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024
From Cellectis Inc.
Via GlobeNewswire
Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress
From Cellectis Inc.
Via GlobeNewswire
Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety
From Cellectis Inc.
Via GlobeNewswire
Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
From Cellectis Inc.
Via GlobeNewswire
Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
From Cellectis Inc.
Via GlobeNewswire
CLLS Stock Earnings: Cellectis Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Cellectis Provides Financial Results for the Second Quarter 2024
From Cellectis Inc.
Via GlobeNewswire
FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment
From Cellectis Inc.
Via GlobeNewswire
FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
From Cellectis Inc.
Via GlobeNewswire
Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024
From Cellectis Inc.
Via GlobeNewswire
Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing
From Cellectis Inc.
Via GlobeNewswire
Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
From Cellectis Inc.
Via GlobeNewswire
Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia
From Cellectis Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.